Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial demonstrates reduced mortality and hospitalization with eplerenone in systolic heart failure and mild symptoms, highlighting clear therapeutic benefit.
Key Points
- To assess the efficacy of eplerenone compared with placebo in reducing mortality and hospitalization among patients with systolic heart failure and mild symptoms.
- Placebo-controlled randomized clinical trial (ClinicalTrials.gov: NCT00232180).
- Enrolled patients diagnosed with systolic heart failure presenting with mild clinical symptoms.
- Eplerenone reduced the risk of death compared with placebo.
- Eplerenone reduced the risk of hospitalization compared with placebo.
Cite This Study
Zannad et al. (2010) studied this question.